# A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

> **NCT06719011** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 177 (estimated)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** NNC0174-1213 A
- **DRUG:** Cagrilintide B
- **DRUG:** Placebo A (NNC0174 1213 A)

## Key facts

- **NCT ID:** NCT06719011
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2026-03-26
- **Final completion:** 2026-05-17
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719011, "A Study on How NNC0174-1213 Works in People With Overweight or Obesity.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06719011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*